Observational studyFrontiers in immunology2025

The efficacy and safety of tislelizumab combined with weekly nab-paclitaxel, carboplatin, and cetuximab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a real-world study.

Zhanyong Ouyang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.